Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine.

What Was Tested

Researchers studied Bridged Bicyclo Compounds, Heterocyclic in the context of migraine in this randomized controlled trial publication.

This study evaluated the CGRP receptor antagonist MK-3207 for acute treatment of migraine.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled, multicenter and parallel-group.

Random assignment meant chance, not the researchers, decided who got Bridged Bicyclo Compounds, Heterocyclic and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Bridged Bicyclo Compounds, Heterocyclic, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Bridged Bicyclo Compounds, Heterocyclic could be set against what happens without it.

Running at several centres spread the Bridged Bicyclo Compounds, Heterocyclic study over different clinics and patient groups.

The primary endpoint was two-hour pain freedom.

What Was Measured

This study evaluated the CGRP receptor antagonist MK-3207 for acute treatment of migraine.

Topics PubMed links to this paper include Acute Disease, Bridged Bicyclo Compounds, Heterocyclic, Calcitonin Gene-Related Peptide Receptor Antagonists, Migraine Disorders, Placebo Effect and Spiro Compounds.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Bridged Bicyclo Compounds, Heterocyclic in people with migraine.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (Cephalalgia : an international journal of headache), a journal based in England.

More context: Migraine research.